Thyroid Gland Oncocytic Follicular Carcinoma
NCI Definition: A follicular carcinoma of the thyroid gland, characterized by the presence of large cells with eosinophilic granular cytoplasm and pleomorphic nuclei with prominent, eosinophilic nucleoli. The nuclear features that characterize the papillary carcinomas of the thyroid gland are absent. 
Thyroid gland oncocytic follicular carcinomas most frequently harbor alterations in TBX3, TP53, PTEN, and NF1 .
TP53 Mutation, TBX3 Amplification, PTEN Mutation, and NF1 Mutation are the most common alterations in thyroid gland oncocytic follicular carcinoma .
There are 3 clinical trials for thyroid gland oncocytic follicular carcinoma, of which 3 are open and 0 are completed or closed. Of the trials that contain thyroid gland oncocytic follicular carcinoma as an inclusion criterion, 1 is early phase 1 (1 open) and 2 are phase 2 (2 open).
Durvalumab, everolimus, and iodine i-131 are the most common interventions in thyroid gland oncocytic follicular carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.